Ranibizumab, which targets human VEGFA and does not have an Fc region, is effective in treating neovascular AMD in humans.31,32 We sought to compare the relative anti-angiogenic efficacies of bona fide VEGFA targeting and of FcγR-mediated signaling. The gene discussed is VEGFA; the disease is age-related macular degeneration.